# Triazolo pyrimidine derivatives of coumarin and benzocoumarin: green synthesis, biological activity screening study with in silico evaluation

**Authors:** Hawazen M. Hassanain, Meaad J. Al-Zahrani, Roaa M. Alreemi, Huda A. Al-Ghamdi, Ahlam I. Al-Sulami, Khadijah M. Al-Zaydi

PMC · DOI: 10.1186/s13065-025-01636-6 · BMC Chemistry · 2025-10-14

## TL;DR

This study develops green-synthesized triazolo pyrimidine coumarin and benzocoumarin compounds with potential as anticancer and antiviral agents, showing good biological activity and drug-like properties.

## Contribution

The paper introduces a green synthesis method for triazolo pyrimidine coumarin and benzocoumarin derivatives with in silico evaluation of their drug potential against multiple disease targets.

## Key findings

- Benzocoumarin derivatives showed better performance than coumarin compounds against three disease targets.
- Both compounds were predicted to be efficiently absorbed and cross the blood-brain barrier.
- The compounds exhibited promising pharmacokinetic and toxicity profiles suitable for early-stage drug development.

## Abstract

In the current study, triazolo pyrimidine coumarin and benzocoumarin derivatives were prepared using green methods as a fast and cost-efficient strategy in comparison with the traditional method in terms of reaction time and yield. Combining coumarins with other bioactive compounds could improve the anticancer properties and other biological activities. Therefore, both compounds were evaluated in silico as potential early-stage small molecule inhibitors of three targets, which cause four life-threatening diseases: leukaemia FLT3 (PDB: 4XUF), SARS-COV-2 (3CLpro) (PDB: 6M2N), and adenosine A1 receptors A1R (PDB: 5N2S), which could cause heart failure and Alzheimer’s disease. It was discovered that both compounds show promising results against the three targets. However, benzocoumarin shows an advantage over coumarin compounds. The effects of modifications to the coumarin core have been studied using an in silico technique that evaluates pharmacokinetics, absorption, distribution, metabolism, excretion, and toxicity of these compounds, showing promising results as an early-stage drug. However, both compounds were predicted to be highly absorbed from the gastrointestinal tract and enter the blood-brain barrier efficiently. The predicted oral toxicity of both compounds was LD50 = 350 mg/kg, putting both of them in the IV toxicity class. The optical properties of coumarin and benzocoumarin compounds were also investigated.

The online version contains supplementary material available at 10.1186/s13065-025-01636-6.

## Linked entities

- **Proteins:** FLT3 (fms related receptor tyrosine kinase 3), Adora1 (adenosine A1 receptor)
- **Chemicals:** triazolo pyrimidine (PubChem CID 64962), coumarin (PubChem CID 323), benzocoumarin (PubChem CID 9543378)
- **Diseases:** leukaemia (MONDO:0004355), SARS-COV-2 (MONDO:0100096), heart failure (MONDO:0005252), Alzheimer’s disease (MONDO:0004975)

## Full-text entities

- **Genes:** ORF1ab (ORF1a polyprotein;ORF1ab polyprotein) [NCBI Gene 43740578], FLT3 (fms related receptor tyrosine kinase 3) [NCBI Gene 2322] {aka CD135, FLK-2, FLK2, STK1}
- **Diseases:** toxicity (MESH:D064420), heart failure (MESH:D006333), leukaemia (MESH:D015458), Alzheimer's disease (MESH:D000544)
- **Chemicals:** coumarins (MESH:D003374), coumarin (MESH:C030123), Triazolo pyrimidine (-)
- **Species:** Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12519810/full.md

## Figures

11 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12519810/full.md

---
Source: https://tomesphere.com/paper/PMC12519810